Skip to main content

Table 3 Modifications in PaCO2 values during follow-up period in study population stratified by intervention (high flow nasal therapy and noninvasive ventilation)

From: High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial

  HFNT group NIV group p value
Per-protocol 2 h    
PaCO2 (mmHg) on patients who completed the treatment originally allocated at 2 h, mean ± SD    
 Subjects, n 34 37
 At baseline ( T0) 74.0 ± 13.5 72.2 ± 13.3 0.5845
 After 2 h ( T2h ) 67.2 ± 16.4 62.7 ± 13.5 0.1933
 After 6 h ( T6h ) 64.5 ± 15.8 57.9 ± 12.2 0.0630
 ΔT2hT0 − 6.8 ± 8.7 − 9.5 ± 8.5 0.4040
 ΔT6hT0 − 9.5 ± 13.0 − 14.3 ± 11.1 0.0962
 ΔT6hT2h − 2.7 ± 9.7 − 4.8 ± 7.1 0.1637
Per-protocol 6 h    
PaCO2 (mmHg) on patients who completed the treatment originally allocated at 6 h, mean ± SD    
 Subjects, n 24 29
 At baseline ( T0) 72.7 ± 10.3 74.0 ± 13.7 0.7955
 After 2 h ( T2h ) 64.7 ± 8.7 63.7 ± 14.5 0.7493
 After 6 h ( T6h ) 61.4 ± 7.7 59.8 ± 12.6 0.5632
 ΔT2hT0 − 8.0 ± 6.5 − 10.3 ± 8.9 0.5200
 ΔT6hT0 − 11.3 ± 7.3 − 14.2 ± 12.0 0.4475
 ΔT6hT2h − 3.3 ± 6.9 − 3.9 ± 7.6 0.8163
Intention-to-treat analysis    
PaCO2 (mmHg) of enrolled patients, mean ± SD    
 Subjects, n 40 39  
 At baseline ( T0) 73.7 ± 12.8 72.0 ± 13.0 0.5270
 After 2 h ( T2h ) 68.2 ± 15.6 63.4 ± 13.6 0.1387
 After 6 h ( T6h ) 64.0 ± 14.9 58.1 ± 12.4 0.0610
 ΔT2hT0 − 5.5 ± 9.3 − 8.6 ± 9.3 0.2940
 ΔT6hT0 − 9.7 ± 13.2 − 13.9 ± 11.3 0.1329
 ΔT6hT2h − 4.2 ± 11.1 − 5.3 ± 7.5 0.3670
  1. HFNT high flow nasal therapy, NIV noninvasive ventilation, PaCO2 partial pressure of carbon dioxide, SD standard deviation, Δ difference in PaCO2 values between timepoints